Elite Pharmaceuticals, Inc. Debt Related Commitment Fees and Debt Issuance Costs
Elite Pharmaceuticals, Inc. (ELTP) reported Debt Related Commitment Fees and Debt Issuance Costs of $158.93 thousand for the 3-month period ending 2025-06-30, per its 10-Q filed 2025-08-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:DebtRelatedCommitmentFeesAndDebtIssuanceCosts · last filed 2025-08-14
- Elite Pharmaceuticals, Inc. debt related commitment fees and debt issuance costs for the quarter ending 2025-06-30 was $158.93K, a 36.63% decline year-over-year.
- Elite Pharmaceuticals, Inc. debt related commitment fees and debt issuance costs for the quarter ending 2025-03-31 was $188.84K, a 13.03% decline year-over-year.
- Elite Pharmaceuticals, Inc. debt related commitment fees and debt issuance costs for the quarter ending 2024-12-31 was $77.61K, a 36.19% decline year-over-year.
- Elite Pharmaceuticals, Inc. debt related commitment fees and debt issuance costs for the quarter ending 2024-09-30 was $255.14K, a 95.60% increase year-over-year.
- Elite Pharmaceuticals, Inc. debt related commitment fees and debt issuance costs for fiscal 2025 was $772.37K, a 31.22% increase from fiscal 2024.
- Elite Pharmaceuticals, Inc. debt related commitment fees and debt issuance costs for fiscal 2024 was $588.62K.
| Period end | Debt Related Commitment Fees and Debt Issuance Costs 3 month | Debt Related Commitment Fees and Debt Issuance Costs 6 month | Debt Related Commitment Fees and Debt Issuance Costs 9 month | Debt Related Commitment Fees and Debt Issuance Costs 12 month |
|---|---|---|---|---|
| 2025-06-30 | $158.93K 10-Q · filed 2025-08-14 | $347.77K derived: sum of 2 quarters · filed 2025-08-14 | $425.38K derived: sum of 3 quarters · filed 2025-08-14 | $680.51K derived: sum of 4 quarters · filed 2025-08-14 |
| 2025-03-31 | $188.84K derived: 10-K 12 month − 10-Q 9 month · filed 2025-06-30 | $266.45K derived: sum of 2 quarters · filed 2025-06-30 | $521.59K derived: sum of 3 quarters · filed 2025-06-30 | $772.37K 10-K · filed 2025-06-30 |
| 2024-12-31 | $77.61K 10-Q · filed 2025-02-13 | $332.74K derived: sum of 2 quarters · filed 2025-02-13 | $583.52K 10-Q · filed 2025-02-13 | $800.67K derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-09-30 | $255.14K 10-Q · filed 2024-11-14 | $505.92K 10-Q · filed 2024-11-14 | $723.06K derived: sum of 3 quarters · filed 2025-08-14 | $844.69K derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-06-30 | $250.78K 10-Q · filed 2025-08-14 | $467.93K derived: sum of 2 quarters · filed 2025-08-14 | $589.55K derived: sum of 3 quarters · filed 2025-08-14 | $719.99K derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $217.14K derived: 10-K 12 month − 10-Q 9 month · filed 2025-06-30 | $338.77K derived: sum of 2 quarters · filed 2025-06-30 | $469.21K derived: sum of 3 quarters · filed 2025-06-30 | $588.62K 10-K · filed 2025-06-30 |
| 2023-12-31 | $121.63K 10-Q · filed 2025-02-13 | $252.07K derived: sum of 2 quarters · filed 2025-02-13 | $371.48K 10-Q · filed 2025-02-13 | |
| 2023-09-30 | $130.44K 10-Q · filed 2024-11-14 | $249.85K 10-Q · filed 2024-11-14 | ||
| 2023-06-30 | $119.41K 10-Q · filed 2024-08-14 |